Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The cure rate for Gilead’s new treatment is comparable to what has been seen in people who have only hep C.
A new study examines factors that predicted which black men who have sex with men (MSM) would better stick with the daily Truvada regimen.
But will there be enough money to keep pushing the dial?
The accompanying editorial and press release to recent PARTNER study findings spark concerns from the Prevention Access Campaign.
Meanwhile, their rates of other liver health problems are falling.
Why is that? Researchers offer a theory.
Starting HIV meds within 15 days of infection prevented the development of antibodies.
But some hard-hit risk groups and areas have been slow to adopt the HIV prevention method.
The trial will test giving the treatment every four weeks, which has controlled HIV better than the eight-week dosing schedule.
The open-label phase of the intercourse-based PrEP dosing study indicates the apparent risk-reduction power of the protocol.
The program also boosted the rates of HIV diagnosis and treatment.
U.S. PEPFAR funding favors nations with generalized epidemics.
Teenage gay and bi men's adherence to PrEP, good with monthly monitoring, declined with quarterly monitoring in a recent study.
Investigators have created a consortium hoping to yield HIV cures through stem cell transplants like the ones that cured the Berlin Patient.
Studies have shed new light onto why young women in South Africa have high rates of HIV infection and how to prevent the virus's spread.
Couples who received PrEP as a “bridge” to HIV treatment lowered their risk of transmission by 95 percent.